| First Author | Chen Y | Year | 2019 |
| Journal | J Neurochem | Volume | 148 |
| Issue | 2 | Pages | 252-274 |
| PubMed ID | 30431158 | Mgi Jnum | J:270107 |
| Mgi Id | MGI:6274861 | Doi | 10.1111/jnc.14627 |
| Citation | Chen Y, et al. (2019) Increased alpha2delta-1-NMDA receptor coupling potentiates glutamatergic input to spinal dorsal horn neurons in chemotherapy-induced neuropathic pain. J Neurochem 148(2):252-274 |
| abstractText | Painful peripheral neuropathy is a severe and difficult-to-treat neurological complication associated with cancer chemotherapy. Although chemotherapeutic drugs such as paclitaxel are known to cause tonic activation of presynaptic NMDA receptors (NMDARs) to potentiate nociceptive input, the molecular mechanism involved in this effect is unclear. alpha2delta-1, commonly known as a voltage-activated calcium channel subunit, is a newly discovered NMDAR-interacting protein and plays a critical role in NMDAR-mediated synaptic plasticity. Here we show that paclitaxel treatment in rats increases the alpha2delta-1 expression level in the dorsal root ganglion and spinal cord and the mRNA levels of GluN1, GluN2A, and GluN2B in the spinal cord. Paclitaxel treatment also potentiates the alpha2delta-1-NMDAR interaction and synaptic trafficking in the spinal cord. Strikingly, inhibiting alpha2delta-1 trafficking with pregabalin, disrupting the alpha2delta-1-NMDAR interaction with an alpha2delta-1 C-terminus-interfering peptide, or alpha2delta-1 genetic ablation fully reverses paclitaxel treatment-induced presynaptic NMDAR-mediated glutamate release from primary afferent terminals to spinal dorsal horn neurons. In addition, intrathecal injection of pregabalin or alpha2delta-1 C-terminus-interfering peptide and alpha2delta-1 knockout in mice markedly attenuate paclitaxel-induced pain hypersensitivity. Our findings indicate that alpha2delta-1 is required for paclitaxel-induced tonic activation of presynaptic NMDARs at the spinal cord level. Targeting alpha2delta-1-bound NMDARs, not the physiological alpha2delta-1-free NMDARs, may be a new strategy for treating chemotherapy-induced neuropathic pain. OPEN SCIENCE BADGES: This article has received a badge for *Open Materials* because it provided all relevant information to reproduce the study in the manuscript. The complete Open Science Disclosure form for this article can be found at the end of the article. More information about the Open Practices badges can be found at https://cos.io/our-services/open-science-badges/. |
